Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,100,542
  • Shares Outstanding, K 164,092
  • Annual Sales, $ 92,850 K
  • Annual Income, $ -386,210 K
  • 60-Month Beta -0.17
  • Price/Sales 100.33
  • Price/Cash Flow N/A
  • Price/Book 19.31
Trade LEGN with:

Options Overview Details

View History
  • Implied Volatility 72.18% ( +3.23%)
  • Historical Volatility 38.18%
  • IV Percentile 45%
  • IV Rank 42.32%
  • IV High 109.62% on 02/16/22
  • IV Low 44.71% on 08/09/22
  • Put/Call Vol Ratio 1.78
  • Today's Volume 25
  • Volume Avg (30-Day) 280
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 11,525
  • Open Int (30-Day) 12,389

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate -0.70
  • Number of Estimates 4
  • High Estimate -0.60
  • Low Estimate -0.74
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -62.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
47.49 +12.32%
on 11/22/22
56.25 -5.17%
on 12/08/22
+1.84 (+3.57%)
since 11/09/22
3-Month
37.30 +43.00%
on 10/12/22
56.25 -5.17%
on 12/08/22
+8.83 (+19.84%)
since 09/09/22
52-Week
30.75 +73.44%
on 03/14/22
57.67 -7.51%
on 07/07/22
+2.08 (+4.06%)
since 12/09/21

Most Recent Stories

More News
Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today...

LEGN : 53.55 (-3.44%)
Legend Biotech Announces Participation in Upcoming Investor Conferences

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced...

LEGN : 53.55 (-3.44%)
Legend Biotech Shares Updated Data from Comprehensive Cilta-Cel Clinical Development Program at ASH 2022

Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that seven company-sponsored...

LEGN : 53.55 (-3.44%)
Legend's (LEGN) Q3 Carvykti Preliminary Sales Top Expectations

Legend Biotech (LEGN) reports $55 million as preliminary sales figures for its multiple myeloma therapy in third-quarter 2022. Shares rise 14.2% post the announcement.

BMY : 79.00 (-1.10%)
JNJ : 176.56 (-0.36%)
BLUE : 7.59 (-3.19%)
LEGN : 53.55 (-3.44%)
Why Legend Biotech's Shares Jumped 14.2% On Tuesday

The company presented news regarding early revenue figures for a multiple myeloma therapy it collaborated on.

BLUE : 7.59 (-3.19%)
JNJ : 176.56 (-0.36%)
BMY : 79.00 (-1.10%)
LEGN : 53.55 (-3.44%)
Jobs Numbers Roll out Ahead of Canadian Long Weekend

Monday U.S. Economic Lookahead S&P U.S. manufacturing PMI (Sept.) ISM manufacturing ...

TMQ.TO : 0.80 (-2.44%)
NEXT.TO : 2.97 (-1.00%)
KOR.TO : 4.09 (-0.24%)
LEGN : 53.55 (-3.44%)
NEXT : 4.45 (-3.89%)
AZRE : 4.92 (+3.58%)
AYI : 177.84 (-0.55%)
SGH : 16.74 (+0.54%)
SAR : 26.30 (+1.04%)
LW : 86.14 (-0.42%)
RPM : 103.76 (+0.09%)
HELE : 100.08 (+0.23%)
CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Legend Biotech Corporation (NASDAQ: LEGN), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, announced today that Japan’s...

LEGN : 53.55 (-3.44%)
Stocks Tumble as October Approaches

Monday U.S. Economic Lookahead Chicago Fed national activity index (Aug.) Featured ...

ACB.VN : 2.690 (+0.37%)
VIV.VN : 0.080 (-5.88%)
VOTI.VN : 0.015 (-40.00%)
LEGN : 53.55 (-3.44%)
NEXT : 4.45 (-3.89%)
LEGH : 18.69 (+0.43%)
JBL : 71.76 (+0.01%)
DAVA : 78.58 (+0.86%)
CALM : 58.45 (-1.07%)
PAYX : 119.87 (-0.24%)
CTAS : 455.37 (+0.05%)
MTN : 257.88 (+2.66%)
Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced...

LEGN : 53.55 (-3.44%)
U.S. Hears Inflation News Next Week

Monday U.S. Featured Earnings Oracle Corporation (NYSE:ORCL) (Q1) EPS projects for 88 cents, ...

ORCL : 80.15 (+0.10%)
LEGN : 53.55 (-3.44%)
NEXT : 4.45 (-3.89%)
CNM : 20.59 (-0.72%)
INNV : 7.44 (-2.87%)
LICY : 5.70 (-1.04%)
TNP : 17.07 (+0.12%)
LPTH : 1.1352 (-1.00%)
MYTE : 10.10 (-1.46%)
MANU : 21.27 (-2.65%)
FAF.TO : 1.20 (+15.38%)
CXI.TO : 18.48 (-2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 58.69
2nd Resistance Point 57.47
1st Resistance Point 56.47
Last Price 53.55
1st Support Level 54.24
2nd Support Level 53.02
3rd Support Level 52.02

See More

52-Week High 57.67
Last Price 53.55
Fibonacci 61.8% 47.39
Fibonacci 50% 44.21
Fibonacci 38.2% 41.04
52-Week Low 30.75

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar